Don Nicholson

Today, we reported positive topline results from our Phase 1a clinical study of JNT-517, a potential first-in-class oral treatment for #PKU. JNT-517 demonstrated proof of mechanism and was safe and well tolerated. The Phase 1b is now open for enrollment. ow.ly/3Swq50OAIW3

Disc Medicine will be heading to NYC to ring the opening bell at @Nasdaq. Save the date to join us on Friday at 9:30 am ET, livestream link coming soon.

So much credit & a big 'thank you' to @DonWNicholson for driving us to go after the JH2/allosteric domain of TYK2 as he always said “TYK2 is the most elegant and genetically validated drug target for I&I diseases" bit.ly/3FD3YZ4

Today, we shared positive clinical data from our KT-474 Phase 1 hidradenitis suppurativa and atopic dermatitis patient cohort, as well as updates on our three oncology programs, KT-413, KT-333 and KT-253. For more information, please visit: bit.ly/3HwYOAE

Congrats to @LifeSciVC as well, who co-founded this company and was first CEO and continues to serve as Chair. Big thanks as well to my mentor @DonWNicholson who proceeded me as CEO and was a staunch supporter of pivoting to the allosteric pocket of TYK2.